Table 1 Clinicopathological and molecular data of patients with differentiated thyroid cancer (DTC) included in the study

Total (%)

98 (100)

15 (15.3)

23 (23.5)

60 (61.2)

Age (n)

98

15

23

60

 Mean (years)

43 ± 1.6

53 ± 3.9

43 ± 3.1

40 ± 2.1

Tumour size (n)

93

15

22

56

 Mean (cm)

2.8 ± 0.18

3.9 ± 0.46

2.4 ± 0.30

2.7 ± 0.24

Gender (n)

98

15

23

60

 Female (%)

84 (85.7)

12 (80)

19 (82.6)

53 (88.3)

 Male (%)

14 (14.3)

3 (20)

4 (17.4)

7 (11.7)

Capsule (n)

88

15

21

52

 Positive (%)

45 (51.1)

15 (100)

9 (42.9)

21 (40.4)

Capsular invasion (n)

42

15

8

19

 Positive (%)

27 (64.3)

15 (100)

2 (25.0)

10 (52.6)

Vascular invasion (n)

89

15

21

53

 Positive (%)

48 (53.9)

11 (73)

5 (23.8)

32 (60.4)

Lymph node metastasis (n)

93

15

21

57

 Positive (%)

24 (25.8)

–

4 (19.0)

20 (35.1)

Extrathyroidal extension (n)

88

15

21

52

 Positive (%)

27 (30.7)

1 (6.67)

2 (9.52)

24 (46.2)

Distant metastasis (n)

93

15

21

57

 Positive (%)

5 (5.38)

1 (6.67)

–

4 (7.02)

Lymphocytic thyroiditis (n)

91

15

22

54

 Positive (%)

40 (44.0)

4 (26.7)

8 (36.4)

28 (51.9)

Oncocytic (n)

89

15

21

53

 Positive (%)

17 (19.1)

6 (40.0)

–

11 (20.8)

PAX8-PPARG rearrangements (n)

98

15

23

60

 Positive (%)

2 (2.04)

1 (6.67)

1 (4.35)

–

RET/PTC rearrangements (n)

98

15

23

60

 Positive (%)

17 (17.3)

1 (6.67)

3 (13.0)

13 (21.7)

RET/PTC1 rearrangement (n)

98

15

23

60

 Positive (%)

12 (12.2)

1 (6.67)

1 (4.35)

10 (16.7)

RET/PTC3 rearrangement (n)

98

15

23

60

 Positive (%)

2 (2.04)

–

1 (4.35)

1 (1.67)

BRAF mutation (n)

98

15

23

60

 Positive (%)

21 (21.4)

–

2 (8.70)

19 (31.7)

NRAS mutation (n)

98

15

23

60

 Positive (%)

16 (16.3)

5 (33.3)

5 (21.7)

6 (10.0)

TERT promoter mutation (n)

98

15

23

60

 Positive (%)

3 (3.06)

2 (13.3)

1 (4.35)

–